Business Context and Reporting Period
This Form 8-K filing by Aerpio Pharmaceuticals, Inc. (trading symbol: ARPO) reports on the Annual Meeting of Stockholders held on June 18, 2019. The record date for the meeting was April 22, 2019, with 40,588,004 outstanding shares of common stock. The filing does not contain financial performance data for a specific reporting period as it focuses solely on corporate governance events.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding stockholder voting results and does not include financial statements.
Material Changes
No material financial changes are reported in this filing. The primary event is the successful ratification of corporate governance proposals by the stockholders.
Guidance, Outlook, and Voting Results
Stockholders approved two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected Anupam Dalal, Pravin Dugel, and Steven Prelack as Class II directors for three-year terms expiring in 2022. The voting results were as follows:
- Anupam Dalal: 20,462,801 For; 1,202,063 Withhold; 12,066,068 Broker Non-Votes.
- Pravin Dugel: 20,458,243 For; 1,206,621 Withhold; 12,066,068 Broker Non-Votes.
- Steven Prelack: 20,465,288 For; 1,199,576 Withhold; 12,066,068 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders approved the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019. The vote was 32,498,947 For, 1,082,676 Against, and 149,309 Abstain.
The filing contains no management commentary on future guidance, risks, or contingencies beyond the standard disclosure of the voting outcomes.
Key Facts for Investor Verification
- Verify the company name discrepancy: The input metadata lists "Whitehawk Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Aerpio Pharmaceuticals, Inc."
- Confirm the high volume of broker non-votes (12,066,068) relative to the "For" votes on director elections, which may indicate significant passive ownership.
- Review the Definitive Proxy Statement filed on April 30, 2019, for detailed biographies of the newly elected directors and the rationale for the auditor appointment.
- Note that this filing does not contain financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.